Prostatic length predicts functional outcomes after iodine-125 prostate brachytherapy

Brachytherapy

Volumn 10, Issue 2, 2011, Pages 107-116

  Pal, Raj P ^a   Bhatt, Jaimin R ^a   Khan, Masood A ^a   Duggleby, Stuart ^a   Camilleri, Philip ^a   Bell, C Richard ^a   Elwell, Christine ^a   Kunkler, Roger B ^a  

^a NORTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Brachytherapy; Prostate cancer; Urinary toxicity

Indexed keywords

IODINE 125;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NEEDLE; NEPHROTOXICITY; ORGAN SIZE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RADIATION DOSE; TREATMENT OUTCOME; URINE RETENTION;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; COMORBIDITY; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROSTATE; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOPHARMACEUTICALS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; URINARY INCONTINENCE;

EID: 79951563737     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2010.06.010     Document Type: Article

References (32)

1. Cancer Research UK. News and Resources Centre. Cancer Stats. Prostate cancer. Available at: Accessed September 2008. http://info.cancerresearchuk.org/cancerstats/.
2. Horninger W., Reissigl A., Rogatsch H., et al. Prostate cancer screening in Tyrol, Austria: Experience and results. Eur Urol 1999, 35:523-538.
3. Wilt T.J., MacDonald R., Rutks I., et al. Systematic review: Comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008, 148:435-448.
4. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974.
5. Anderson J.F., Swanson D.A., Levy L.B., et al. Urinary side effects and complications after permanent prostate brachytherapy: The MD Anderson Cancer Center experience. Urology 2009, 74:601-605.
6. Gutman S., Merrick G.S., Butler W.M., et al. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy. BJU Int 2006, 97:62-68.
7. Mabjeesh N.J., Chen J., Stenger A., et al. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy. Urology 2007, 70:548-553.
8. Merrick G.S., Butler W.M., Wallner K.E., et al. The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy. Brachytherapy 2004, 3:22-29.
9. Landis D., Wallner K., Locke J., et al. Late urinary function after prostate brachytherapy. Brachytherapy 2002, 1:21-26.
10. Crook J., McLean M., Catton C., et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 2002, 52:453-460.
11. Kollmeier M.A., Stock R.G., Cesaretti J., et al. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy. J Urol 2005, 173:808-812.
12. Lee N., Wuu C.S., Brody R., et al. Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000, 48:1457-1460.
13. Locke J., Ellis W., Wallner K., et al. Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: A prospective study. Int J Radiat Oncol Biol Phys 2002, 52:712-719.
14. Martens C., Pond G., Webster D., et al. Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy. Brachytherapy 2006, 5:9-13.
15. Niehaus A., Merrick G.S., Butler W.M., et al. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006, 64:136-143.
16. Merrick G.S., Butler W.M., Lief J.H., et al. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000, 47:121-128.
17. Henderson A., Ismail A.K., Cunningham M., et al. Toxicity and early biochemical outcomes from 125iodine prostate brachytherapy in the UK. A prospective study. Clin Oncol (R Coll Radiol) 2004, 16:95-104.
18. Keyes M., Schellenberg D., Moravan V., et al. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: The effect of learning curve?. Int J Radiat Oncol Biol Phys 2006, 64:825-834.
19. Keyes M., Miller S., Moravan V., et al. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys 2009, 73:1023-1032.
20. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 2008, 53:68-80. European Association of Urology.
21. Stock R.G., Stone N.N., Wesson M.F., et al. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Bio Phys 1995, 32:219-225.
22. Merrick G.S., Wallner K.E., Butler W.M. Minimizing prostate brachytherapy-related morbidity. Urology 2003, 62:786-792.
23. Merrick G.S., Butler W.M., Wallner K.E., et al. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology 2002, 60:650-655.
24. Barry M.J., Fowler F.J., O'Leary M.P., et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992, 148:1549-1557.
25. Terris M.K., Stamey T.A. Determination of prostate volume by transrectal ultrasound. J Urol 1991, 145:984-987.
26. Jepsen J.V., Leverson G., Bruskewitz C. Variability in urinary flow rate and prostate volume: An investigation using the placebo arm of a drug trial. J Urol 1998, 160:1689-1694.
27. Stone N.N., Stock R.G. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology 2007, 69:338-342.
28. Meyer J.P., Bell C.R., Elwell C., et al. Brachytherapy for prostate cancer: Is pretreatment prostate volume important?. BJU Int 2008, 102:1585-1588.
29. Kelly K., Swindell R., Routledge J., et al. Prediction of urinary symptoms after 125iodine prostate brachytherapy. Clin Oncol (R Coll Radiol) 2006, 18:326-332.
30. Eri L.M., Thomassen H., Brennhovd B., et al. Accuracy and repeatability of prostate volume measurements by transrectal ultrasound. Prostate Cancer Prostatic Dis 2002, 5:273-278.
31. Wallner K., Roy J., Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999, 32:465-471.
32. Wehle M.J., Lisson S.W., Buskirk S.J., et al. Prediction of genitourinary tract morbidity after brachytherapy for prostate adenocarcinoma. Mayo Clin Proc 2004, 79:314-317.